EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Historical Review of Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide in Sepsis

Razia Dawlaty iD, Philomena Entsie iD, Emmanuel Boadi Amoafo iD, Elisabetta Liverani iD, Glenn P Dorsam iD

Biology · 22.04.2026 · 15 (9) · 663

DOI: 10.3390/biology15090663 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biology, online erschienen am 22.04.2026. Verfasst von Razia Dawlaty und 4 weiteren Autor:innen. Beteiligte Einrichtung: Plant Pathology, Microbiology, and Biotechnology, North Dakota State University, Fargo, ND 58102, USA. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) have emerged as potent modulators of immune responses during sepsis, yet their roles remain complex, alternating between protective and permissive depending on timing, tissue compartment, and inflammatory context. This review presents a historical assessment of VIP and PACAP in sepsis research, highlighting the evolution of conceptual advances across five decades. Starting in the 1980s, early studies revealed that VIP levels rise during endotoxemia and correlated with hypotension and mortality, suggesting a deleterious role. By the 1990s, research pivoted toward understanding gut-derived VIP and its interaction with nitric oxide, culminating in the classification of VIP and PACAP as “macrophage deactivating factors” that downregulate TNFα and IL-6. The 2000s further clarified their cell-specific actions through VPAC1/2 and PAC1 receptors, showing anti-inflammatory effects on both innate and adaptive immune cells, while illuminating delivery challenges overcome by liposomal encapsulation. The 2010s expanded this narrative by dissecting receptor dynamics, gut barrier regulation, and VIP’s role in neuroimmune crosstalk and thrombo-inflammation. Most recently, studies in the 2020s provide a nuanced view of how VIP suppresses inflammatory damage but also enables pathogen persistence during live bacterial infection, implicating VIP signaling in trade-offs between tolerance and clearance. Across this chronological framework, VIP and PACAP have oscillated between friend, foe, and frenemy, underscoring the importance of context in leveraging their therapeutic potential in sepsis.

Schlagwörter

Stichwörter der Autor:innen

VPAC1VPAC2cytokine stormimmunomodulationinnate immune responseintestinal barrier functionneuroimmune regulationpituitary adenylate cyclase-activating polypeptide (PACAP)sepsisvasoactive intestinal peptide (VIP)

Autor:innen und Institutionen

  • Plant Pathology, Microbiology, and Biotechnology, North Dakota State University, Fargo, ND 58102, USA.
  • Departments of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58102, USA.

ORCID-Profile: Razia Dawlaty, Philomena Entsie, Emmanuel Boadi Amoafo, Elisabetta Liverani, Glenn P Dorsam

Zitieren

APA

Dawlaty, R., Entsie, P., Amoafo, E. B., Liverani, E., & Dorsam, G. P. (2026). A Historical Review of Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide in Sepsis. Biology, 15(9), 663. https://doi.org/10.3390/biology15090663

Vancouver

Dawlaty R, Entsie P, Amoafo EB, Liverani E, Dorsam GP. A Historical Review of Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide in Sepsis. Biology. 2026;15(9):663. doi:10.3390/biology15090663

BibTeX
@article{Dawlaty2026,
  author = {Dawlaty, Razia and Entsie, Philomena and Amoafo, Emmanuel Boadi and Liverani, Elisabetta and Dorsam, Glenn P},
  title = {A Historical Review of Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide in Sepsis},
  journal = {Biology},
  year = {2026},
  volume = {15},
  number = {9},
  pages = {663},
  doi = {10.3390/biology15090663}
}
Kostenlos starten →